Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. They currently have $7.75 price objective on the biotechnology company’s stock.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Separately, HC Wainwright reaffirmed a buy rating on shares of Kamada in a research note on Tuesday, November 23rd.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Sunday, November 21st. The biotechnology company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.05). The business had revenue of $23.03 million during the quarter, compared to analysts’ expectations of $25.20 million. Kamada had a net margin of 4.25% and a return on equity of 2.44%. During the same quarter last year, the firm earned $0.15 earnings per share. Equities analysts forecast that Kamada will post 0.05 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in shares of Kamada in the second quarter worth approximately $73,000. Geode Capital Management LLC boosted its stake in Kamada by 7.7% during the third quarter. Geode Capital Management LLC now owns 25,878 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,856 shares during the last quarter. Susquehanna International Group Ltd. acquired a new position in Kamada during the third quarter worth $141,000. O Shaughnessy Asset Management LLC acquired a new position in Kamada during the second quarter worth $172,000. Finally, Goldman Sachs Group Inc. boosted its stake in Kamada by 8.3% during the second quarter. Goldman Sachs Group Inc. now owns 39,863 shares of the biotechnology company’s stock worth $232,000 after buying an additional 3,068 shares during the last quarter. 20.41% of the stock is currently owned by hedge funds and other institutional investors.
Kamada Company Profile
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the following segments: Proprietary Products and Distribution. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use.
Recommended Story: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.